Cadila Pharmaceuticals Ltd

Company Name:Cadila Pharmaceuticals Ltd
OldName:
Group :
Address:Corp Office
Sarkhej-Dholka Road,
Bhat
City:Sarkhej 382210 Ahmedabad Gujarat
Tel:02718-225001
Fax:02718-225039
Mktg-Email :
HR-Email :
Purchase-Email :
Brands Owned :

About the Company :


Cadila Pharmaceuticals Limited was founded in 1951, by Late Mr. Indravadan I. Modi and Late Mr. Ramanbhai B. Patel. Subsequently, in 1995, it was bifurcated into two different companies namely Cadila Healthcare Limited, part of Patel group and Cadila, part of Modi group. Cadila manufactures both formulations and API drugs for more than 45 therapeutic areas.

The company has two API manufacturing facilities located at Ankleshwar (Gujarat), one formulation facility at Dholka (Gujarat) which is USFDA approved and one formulation facility at Samba in Jammu. Cadila also has state of art R&D centre at Dholka. Cadila also has formulation facilities in Ethiopia through its 57.50% Joint Venture (JV). Cadila exports its products to various countries through its marketing set up in USA, Japan, Africa and Russia. Currently, Cadila is ranked 26th with around 0.96% market share in the Indian Pharmaceuticals Market

 

Cadila Healthcare receives USFDA approval for Haloperidol Decanoate injection

Cadila Healthcare has received USFDA approval for Haloperidol Decanoate injection used in treatment of schizophrenia. It is also used in ...

Cadila group receives USFDA approval for Ranolazine Extended-Release

Zydus Cadila has received final USFDA approval to market generic Ranolazine Extended-Release tablets used for treatment of chronic angina in ...

Cadila Pharma receives GLPC certification for its Dholka facility

Cadila Pharma has received the Good Laboratory Practices Certification (GLP) from National Good Laboratory Practice compliance Monitoring Authority (NGCMA), Department ...

Cadial receives USFDA approval for Chlorthalidone

Zydus Cadila has received final USFDA to market Chlorthalidone tablets, used to treat high blood pressure. The drug will be ...

Cadila receives USFDA approval for Ambrisentan

Zydus Cadila has received final USFDA approval to market Ambrisentan tablets in in strengths of 5 mg and 10 mg ...

Cadila receives USFDA approval for potassium chloride extended release tablets

Cadila has received USFDA approval for Potassium Chloride extended-release capsules to market the same in United States. The product is ...

Cadila receives USFDA approval for Acetazolamide ER

Zydus Cadila has received the final USFDA approval to market Acetazolamide ER Capsules. Acetazolamide is a potent carbonic anhydrase inhibitor ...

Cadila receives USFDA approval for Aripiprazole

Cadila has received final USFDA approval to market antipsychotic drug Aripiprazole tablets in US markets. The drug will be marketed ...

Cadila Group has received USFDA approval for Doxycycline Hyclate and Febuxostat

Zydus Cadila has received final USFDA approval to market Doxycycline Hyclate delayed-release tablets which are used to treat bacterial infections ...

Zydus Cadila receives USFDA approval for Lansoprazole

Zydus Cadila has received final USFDA approval to market generic Lansoprazole delayed release orally disintegrating tablets in the strengths of ...

 

Other Office Address
Plant PlantSurvey No. 1389, Trasad Road, Dholka Dholka 387810 Ahmedabad Gujarat Tel: 02714-221481 Fax: 02714-220315
Plant SBU294, GIDC Estate, Ankleshwar Ankleshwar 393002 Bharuch Gujarat Tel: 02646–223846, 252626, 251519 Fax: 02646 – 250051
Plant Survey No. 342, Nani Kadi, Taluka Kadi Nani Kadi 382715 Mehsana Gujarat Tel: 02764-262463, 262463, 242037, 242194 Fax: 02764 – 242223
Plant Agro Division, 755, Prakruti Farm, Village Hirapur Hirapur 382435 Ahmedabad Gujarat Tel: 9099886000/8980806724/5/6
Corp Office Sarkhej-Dholka Road, Bhat Sarkhej 382210 Ahmedabad Gujarat 02718-225001 02718-225039